Các kết quả do bệnh nhân báo cáo nào được bệnh nhân khớp nhận thấy quan trọng để theo dõi một cách số hóa? Một nghiên cứu dài hạn thực tế trong ArthritisPower

Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl. 1994;41:86–9. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729–40. Tugwell P, Boers M. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee J Rheumatol. 1993;20(3):555–6. ICHOM. Inflammatory Arthritis Data Collection Reference Guide. 2018. Oude Voshaar MAH, Das Gupta Z, Bijlsma JWJ, Boonen A, Chau J, Courvoisier DS, et al. International consortium for health outcome measurement set of outcomes that matter to people living with inflammatory arthritis: consensus from an international working group. Arthritis Care Res. 2019;71(12):1556–65. Frank L, Basch E, Selby JV. Patient-centered outcomes research I. the PCORI perspective on patient-centered outcomes research. JAMA. 2014;312(15):1513–4. Gabriel SE, Normand SL. Getting the methods right--the foundation of patient-centered outcomes research. N Engl J Med. 2012;367(9):787–90. Methodology Committee of the Patient-Centered Outcomes Research I. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA. 2012;307(15):1636–40. Her M, Kavanaugh A. Patient-reported outcomes in rheumatoid arthritis. Curr Opin Rheumatol. 2012;24(3):327–34. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1:e000019. Dixon W, Michaud K. Using technology to support clinical care and research in rheumatoid arthritis. Curr Opin Rheumatol. 2018;30(3):6. Guidance for industry: participants-reported outcome measures: use in Medical product Development to support labeling claims U.S. Department of Health and Human Services Food and Drug Administration; 2009. Nowell WB. Information patients can provide will strengthen the real-world evidence that matters to them. Clin Pharmacol Ther. 2019;106(1):49–51. Nowell WB, Curtis D, Thai M, Wiedmeyer C, Gavigan K, Venkatachalam S, et al. Digital interventions to build a patient registry for rheumatology research. Rheum Dis Clin N Am. 2019;45(2):173–86. Nowell WB, Curtis JR, Crow-Hercher R. Patient governance in a patient-powered research network for adult rheumatologic conditions. Med Care. 2018;56(10 Suppl 1):S16–21. Agiro A, Chen X, Eshete B, Sutphen R, Bourquardez Clark E, Burroughs CM, et al. Data linkages between patient-powered research networks and health plans: a foundation for collaborative research. J Am Med Inform Assoc. 2019;26(7):594–602. Chen X, Agiro A, Nowell WB, Loud S, McBurney R, Young K, et al. Harnessing health plan enrollee data to boost membership in patient-powered research networks. BMC Health Serv Res. 2020;20:1–10. Curtis J, Chen L, Annapureddy N, Clinton C, Clowse M, Long M, Nowell W, Oates J, Rhee R, Singh S, Xie F, Beukelman T. Comparison of Medication New User Definitions in Multi-Specialty EMR Data [abstract]. Arthritis Rheumatol. 2019;71(suppl 10). https://acrabstracts.org/abstract/comparison-of-medication-new-user-definitions-in-multi-specialty-emr-data/. Accessed 3 Feb 2021. NIH. Health Measures [Available from: https://www.healthmeasures.net/. Schiff M, Takeuchi T, Fleischmann R, Gaich CL, DeLozier AM, Schlichting D, et al. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Ther. 2017;19(1):208. Emery P, Blanco R, Maldonado Cocco J, Chen YC, Gaich CL, DeLozier AM, et al. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open. 2017;3(1):e000410. Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88–95. Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2017;76(4):694–700. Bykerk VP, Bingham CO, Choy EH, Lin D, Alten R, Christensen R, et al. Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open. 2016;2(1):e000225. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008;35(11):2136. Yun H, Nowell WB, Curtis D, Willig J, Yang S, Auriemma M, et al. Assessing RA disease activity with PROMIS measures using digital technology. Arthritis Care Res. 2020;72(4):553–60. https://doi.org/10.1002/acr.23888. Barber CEH, Zell J, Yazdany J, Davis AM, Cappelli L, Ehrlich-Jones L, et al. 2019 American College of Rheumatology recommended patient-reported functional status assessment measures in rheumatoid arthritis. Arthritis Care Res. 2019;71(12):1531–9. Bykerk VP, Lie E, Bartlett SJ, Alten R, Boonen A, Christensen R, et al. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA Flare Workshop. J Rheumatol. 2014;41(4):799. Bartlett SJ, Hewlett S, Bingham CO, Woodworth TG, Alten R, Pohl C, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis. 2012;71(11):1855. Kalyoncu U, Dougados M, Daurès JP, Gossec L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2009;68(2):183. Orbai A-M, Bingham CO. Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep. 2015;17(4):28. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):260. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy. Arthritis Care Res. 2008;59(6):785–93. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology. 2013;52(12):2136–48. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology. 2010;49(7):1294–302. Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis. 2002;61(9):818.